In this study, we evaluate dosimetric advantages of using patient‐specific aperture system with intensity‐modulated proton therapy (IMPT) for head and neck tumors at the shallow depth. We used four types of patient‐specific aperture system (PSAS) to irradiate shallow regions less than 4 g/cm2 with a sharp lateral penumbra. Ten head and neck IMPT plans with or without aperture were optimized separately with the same 95% prescription dose and same dose constraint for organs at risk (OARs). The plans were compared using dose volume histograms (DVHs), dose distributions, and some dose indexes such as volume receiving 50% of the prescribed dose (V50), mean or maximum dose (Dmean and Dmax) to the OARs. All examples verified in this study had decreased V50 and OAR doses. Average, maximum, and minimum relative reductions of V50 were 15.4%, 38.9%, and 1.0%, respectively. Dmax and Dmean of OARs were decreased by 0.3% to 25.7% and by 1.0% to 46.3%, respectively. The plans with the aperture over more than half of the field showed decreased V50 or OAR dose by more than 10%. The dosimetric advantage of patient‐specific apertures with IMPT was clarified in many cases. The PSAS has some dosimetric advantages for clinical use, and in some cases, it enables to fulfill dose constraints.
The purpose of this study was to provide periodic quality assurance (QA) methods for respiratory‐gated proton beam with a range modulation wheel (RMW) and to clarify the characteristics and long‐term stability of the respiratory‐gated proton beam. A two‐dimensional detector array and a solid water phantom were used to measure absolute dose, spread‐out Bragg peak (SOBP) width and proton range for monthly QA. SOBP width and proton range were measured using an oblique incidence beam to the lateral side of a solid water phantom and compared between with and without a gating proton beam. To measure the delay time of beam‐on/off for annual QA, we collected the beam‐on/off signals and the dose monitor‐detected pulse. We analyzed the results of monthly QA over a 15‐month period and investigated the delay time by machine signal analysis. The dose deviations at proximal, SOBP center and distal points were −0.083 ± 0.25%, 0.026 ± 0.20%, and −0.083 ± 0.35%, respectively. The maximum dose deviation between with and without respiratory gating was −0.95% at the distal point and other deviations were within ±0.5%. Proximal and SOBP center doses showed the same trend over a 15‐month period. Delay times of beam‐on/off for 200 MeV/SOBP 16 cm were 140.5 ± 0.8 ms and 22.3 ± 13.0 ms, respectively. Delay times for 160 MeV/SOBP 10 cm were 167.5 ± 15.1 ms and 19.1 ± 9.8 ms. Our beam delivery system with the RMW showed sufficient stability for respiratory‐gated proton therapy and the system did not show dependency on the energy and the respiratory wave form. The delay times of beam‐on/off were within expectations. The proposed QA methods will be useful for managing the quality of respiratory‐gated proton beams and other beam delivery systems.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.